Novartis Investigative Site

Fitzroy, Victoria 3065

1 studies enrolling now · 14 studies all time

What they study most

Acute Myelogenous Leukemia, Breast Cancer, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Pain, Early Breast Cancer, Ectopic ACTH Syndrome, Generalized Myasthenia Gravis, Hepatitis C, Leukemia, Myeloid, Chronic Phase, Nelson Syndrome, Neoplasms, Breast, Non-alcoholic Steatohepatitis (NASH)

Studies at this site

• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) — Stopped early
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. — Completed
• Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) — Completed
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants — Completed
• Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants — Completed
• Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients — Completed
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment — Completed
• Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin — Stopped early
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) — Stopped early